High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...
A new publication from Bielefeld University sets a benchmark in optimization research. Together with an international team, Professor Michael Römer from the Faculty of Business Administration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results